Biotech Boomed Even Before Trump’s Election

by | Nov 11, 2016 4:31 pm | Biotechnology, Pharmaceuticals

Now that Donald Trump has transitioned from presidential candidate to president-elect, his pro-business views have cheered many deal makers. His “repeal and replace” pronouncements regarding the Affordable Care Act have chilled some areas of the healthcare market, but others are thriving. Biotechnology is one sector that was already experiencing a boom in mergers and acquisitions, prior to November 8. Third-quarter deal volume surged 58%, to 52 transactions. Sixteen deals were recorded in October 2016, and in the first two weeks of November, 12 are already in our database. Ten of those are license agreements, as pharmaceutical companies swoop in to claim promising product... Read More »

Rehabilitation Deals Still Rising, Thanks to Private Equity

by | Nov 10, 2016 8:57 pm | Private Equity, Rehabilitation

The year isn’t over, and the Rehabilitation sector has already equaled last year’s deal total. Thirty-three deals have been made public through November 11, 2016, compared with 33 in all of 2015. Spending is a bit lower at this point in 2016, at $623 million, down 21% compared with last year’s annual total of $799 million. That may change, depending on the number of deals that disclose prices between now and the end of the year. Four private equity firms have made acquisitions in this sector in 2016. Even though no price was disclosed, the largest was probably from Advent International, which acquired ATI Physical Therapy, a platform company based in Bolingbrook,... Read More »

NASH-Driven Deals Pile Up

by | Nov 9, 2016 5:06 pm | Biotechnology, Pharmaceuticals

On November 10, 2016, Bristol-Meyers Squibb (NYSE: BMY) purchased the exclusive worldwide rights to develop and commercialize Nitto Denko Corporation’s (TYO: 6988) investigational siRNA, which includes Nitto’s lead asset ND-L02-s0201. Nitto’s lead asset ND-L02-s0201 is currently in a five-week open-label Phase 1b study in patients with advanced fibrosis (F3-F4c) due to non-alcoholic steatohepatitis (NASH) or hepatitis C. Nitto Denko received a $100 million upfront payment as part of the license agreement, and it is not the first company to cash in on its product candidates for the possible treatment of NASH. NASH is characterized by fatty infiltration of the liver not caused by alcohol,... Read More »

PSA Healthcare Broadens its Texas Footprint

by | Nov 8, 2016 9:41 pm | Home Health & Hospice, Private Equity

PSA Healthcare, a portfolio company of J.H. Whitney Capital Partners, and a provider of pediatric home care for children with medical complexities, just expanded its presence in Texas to 12 offices with the acquisition of two Texas-based home health care agencies. The targets are Innovations Health Services of Tyler and San Antonio, Texas and Assure Home Healthcare of San Antonio, Texas. Both provide private-duty nursing to medically fragile children and their families in Texas. The Tyler location represents a new market for PSA. The San Antonio offices of Assure and Innovations represent a major investment in one of Texas’ largest markets for pediatric home care. This is PSA’s third... Read More »